Physician profile
Kaitlyn Simpson
NPI 1497311856
$4,443.00
in general payments reported to CMS, 2019-2025
31 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $442 · 2023: $1,377 · 2024: $1,464 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,813 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,813.37 |
| Education | $187.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $637.89 | 2023-2025 | Vraylar, Linzess, Viberzi |
| Bayer Healthcare Pharmaceuticals INC. | $483.36 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $411.83 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $397.83 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $377.96 | 2022-2025 | Mounjaro, Jardiance, Baqsimi |
| Glaxosmithkline, LLC. | $320.93 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $243.58 | 2023-2025 | Veozah |
| Axsome Therapeutics, INC. | $182.70 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $155.55 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $152.94 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.11 | 2023-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $102.17 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.45 | 2023-2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $87.46 | 2024-2025 | Voquezna |
| Lundbeck LLC | $86.67 | 2022-2025 | Rexulti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.21 | 2022-2023 | Trijardy Xr, Tradjenta, Glyxambi |
| Pfizer INC. | $79.54 | 2023-2025 | |
| Insulet Corporation | $57.31 | 2025 | Omnipod |
| Corcept Therapeutics | $51.34 | 2024 | Korlym |
| Mylan Specialty L.P. | $47.76 | 2022-2023 | Yupelri |
| Opko Pharmaceuticals, LLC | $37.65 | 2024-2025 | Rayaldee |
| Idorsia Pharmaceuticals US INC | $36.28 | 2022-2024 | Quviviq |
| Amgen INC. | $31.66 | 2024 | Repatha, Otezla |
| Itamar Medical INC | $27.74 | 2025 | Watchpatone |
| Sumitomo Pharma America, INC. | $19.56 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $18.68 | 2024 | Gardasil 9, Gardasil |
| Paratek Pharmaceuticals, INC. | $18.66 | 2023 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $17.50 | 2023 | Dupixent |
| Esperion Therapeutics, INC. | $16.73 | 2023 | Nexletol |
| Amarin Pharma, INC. | $15.29 | 2022 | |
| Antares Pharma, INC. | $14.66 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.